Preventing diseases of the prostate in the elderly using hormones and nutriceuticals

Aging Male

Volumn 7, Issue 2, 2004, Pages 155-169

  Comhaire, F ^a   Mahmoud, A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

5 reductase inhibitors; Benign prostatic hypertrophy; Food supplementation; Nutriceuticals; Phytoestrogens; Prevention; Prostate; Prostate cancer; Testosterone

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; ANDROGEN; ANDROSTANOLONE; ANTIOXIDANT; DAIDZEIN; DUTASTERIDE; ESTROGEN; EXEMESTANE; FINASTERIDE; FISH OIL; GENISTEIN; LETROZOLE; LONG CHAIN FATTY ACID; LYCOPENE; OMEGA 3 FATTY ACID; PHYTOESTROGEN; PROSTATE SPECIFIC ANTIGEN; RALOXIFENE; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; TAMSULOSIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADHESION; AGING; ANDROGEN BLOOD LEVEL; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CHEEK; CONCENTRATION (PARAMETERS); DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG MECHANISM; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; GERIATRIC CARE; HORMONAL THERAPY; HUMAN; LIBIDO DISORDER; LONG TERM EXPOSURE; NUTRIENT; PATIENT MONITORING; PHILOSOPHY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTIOXIDANTS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT PREPARATIONS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SERENOA;

EID: 4644223703     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/13685530412331284722     Document Type: Review

References (168)

1. Bodin JP, Revol M, Sarrazin R. Anatomy of the anterior male perineum. J Urol Nephrol (Paris) 1978;84:375-86
2. Benoit G, Delmas V, Gillot C. Santorini's venous plexus. Ann Urol (Paris) 1984;18:393-6
3. Lefebvre D, Bastide G, Vaysse P, Roux R, Joly R. Intra- and extra-pelvic venous connections. Anatomical study. Phlebologie 1989;42:385-9
4. Verdonck L, De Slypere JP, Sayed MA, Van Sande M, Van Camp K, Vermeulen A. Subcellular distribution of androgens in hyperplastic human prostate. J Steroid Biochem 1980;13:607-11
5. Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 1999;84:3613-19
6. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40:341-9
7. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001;54:437-45
8. Kawakami E, Amemiya E, Namikawa K, Kashiwagi C, Hori T, Tsutsui T. High plasma estradiol-17beta levels in dogs with benign prostatic hyperplasia and azoospermia. J Vet Med Sci 2001;63:407-12
9. Suzuki K, Ito K, Ichinose Y, et al. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995;29:65-8
10. Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. Arch Androl 2000;44:213-20
11. Hayami S, Sasagawa I, Nakada T. Influence of sex hormones on prostate volume in men on hemodialysis. J Androl 2000;21:258-61
12. Smith P, Rhodes NP, Ke Y, Foster CS. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis 2002;5:105-10
13. Morgentaler A, Bruning CO, III, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. J Am Med Assoc 1996;276:1904-6
14. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7
15. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-8
16. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003;169:1312-15
17. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-82
18. Zagars GK , Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:85-9
19. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-22
20. Kasai S, Sugimura K, Matsumoto K, Nishi N, Kishimoto T, Nakamura T. Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem Biophys Res Commun 1996;228:646-52
21. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8
22. Nishimura K, Kitamura M, Takada S, et al. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 1998;5:276-81
23. Kurimoto S, Moriyama N, Horie S, et al. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998;30:27-32
24. Zhu X , Humphrey PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000;56:1071-4
25. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147:386-96
26. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81
27. Franks LM. Atrophy and hyperplasia in the prostate proper. J Pathol Bactriol 1954;68:617-21
28. Gardner WA Jr, Bennet BD. The prostate-overview: recent insights and speculations. In Weinstein RS, Gardner WA Jr, eds. Pathology and Pathobiology of the Urinary Bladder and Prostate. Baltimore, USA: Williams and Wilkins, 1992:129-48
29. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83
30. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72-9
31. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4
32. Griffiths K, Denis LJ, Turkes A. Other aspects of oestrogen-related endocrinology that relate to prostate cancer and disease progression. In Griffiths K, Denis LJ, Turkes A, eds. Oestrogens, Phyto-oestrogens and the Pathogenesis of Prostatic Disease. London: Martin Dunitz, 2002:313-36
33. Rosenblatt KA, Wicklund KG, Stanford JL. Sexual factors and the risk of prostate cancer. Am J Epidemiol 2001;153:1152-8
34. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82:718-25
35. Copeland WC, Wachsman JT, Johnson FM, Penta JS. Mitochondrial DNA alterations in cancer. Cancer Invest 2002;20:557-69
36. Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT. Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003;334:87-94
37. Chen JZ, Gokden N, Greene GF, Green B, Kadlubar FF. Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hypermutagenesis. Carcinogenesis 2003;24:1481-7
38. Rasmusson GH, Reynolds GF, Steinberg NG, et al. Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding. J Med Chem 1986;29:2298-315
39. Brooks JR, Berman C, Games D, et al. Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors. Prostate 1986;9:65-75
40. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans. Prostate 1989;14:45-53
41. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375-8
42. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70:1136-41
43. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91
44. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation. Br J Urol 1992;70:65-72
45. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57:1073-7
46. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24
47. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41
48. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8
49. Platz EA, Kawachi I, Rimm EB, et al. Plasma steroid hormones, surgery for benign prostatic hyperplasia, and severe lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1999;2:285-9
50. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57:930-5
51. Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990;71:1552-5
52. Foley CL, Kirby RS. 5 alpha-reductase inhibitors: what's new? Curr Opin Urol 2003;13:31-7
53. Pechersky AV, Mazurov VI, Semiglazov VF, et al. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119-25
54. Ito K, Fukabori Y, Shibata Y, et al. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur J Endocrinol 2000;143:543-54
55. Radlmaier A, Eickenberg HU, Fletcher MS, et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 1996;29:199-208
56. Chodak GW, Kolvenbag GJ. Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer? Prostate Cancer Prostatic Dis 2001;4:72-80
57. Kim IY, Kim BC, Seong dH, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002;62:5365-9
58. Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 1993;25:565-9
59. Kondas J, Philipp V, Dioszeghy G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 1996;28:767-72
60. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28:300-6
61. Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 1999;16:231-41
62. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000;164:876-81
63. Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;CD001423
64. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-9
65. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-9
66. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor - new evidence in a coculture model of BPH. Prostate 1999;40:232-41
67. Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol 2002;82:233-9
68. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83
69. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40
70. Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000;3:459-72
71. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000;86:439-42
72. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-506
73. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-75
74. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002;136:42-53
75. Weisser H, Behnke B, Helpap B, Bach D, Krieg M. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 1997;31:97-101
76. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 2000;45:259-66
77. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997;57:299-304
78. Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. [Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism]. Arzneimittelforschung 1992;42:547-51
79. Vacher P, Prevarskaya N, Skryma R, et al. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995;2:357-65
80. Van Coppenolle F, Le B, X, Carpentier F, et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000; 43:49-58
81. Griffiths K, Denis L, Turkes A, Morton MS. Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 1998;12:625-47
82. Naftolin F, Guadalupe SM. Phytoestrogens: are they really estrogen mimics? Fertil Steril 2002; 77:15-17
83. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S-8S
84. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002;186:89-99
85. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85
86. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340-52
87. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302
88. Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 2002;63:1165-76
89. Santti R, Makela S, Strauss L, Korkman J, Kostian ML. Phytoestrogens: potential endocrine disrupters in males. Toxicol Ind Health 1998; 14:223-37
90. Strauss L, Makela S, Joshi S, Huhtaniemi I, Santti R. Genistein exerts estrogen-like effects in male mouse reproductive tract. Mol Cell Endocrinol 1998;144:83-93
91. Goldwyn S, Lazinsky A, Wei H. Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metabol Drug Interact 2000; 17:261-89
92. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001;46:98-107
93. Delclos KB, Bucci TJ, Lomax LG, et al. Effects of dietary genistein exposure during development on male and female CD (Sprague-Dawley) rats. Reprod Toxicol 2001;15:647-63
94. Mousavi Y, Adlercreutz H. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids 1993;58:301-4
95. Habito RC, Montalto J, Leslie E, Ball MJ. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males. Br J Nutr 2000;84:557-63
96. Van P, I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003;166:95-102
97. Channer KS, Jones TH. Cardiovascular effects of testosterone: implications of the "male menopause"? Heart 2003;89:121-2
98. Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HAP. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study. J Clin Endocrinol Metab 2002;87:3632-9
99. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217
100. Nesbitt PD, Lam Y, Thompson LU. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 1999; 69:549-55
101. Tarpila S, Aro A, Salminen I, et al. The effect of flaxseed supplementation in processed foods on serum fatty acids and enterolactone. Eur J Clin Nutr 2002;56:157-65
102. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993;44:147-53
103. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994;50:205-12
104. Makela TH, Wahala KT, Hase TA. Synthesis of enterolactone and enterodiol precursors as potential inhibitors of human estrogen synthetase (aromatase). Steroids 2000;65:437-41
105. Hong SJ, Kim SI, Kwon SM, Lee JR, Chung BC. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 2002;43:236-41
106. Vanharanta M, Voutilainen S, Rissanen TH, Adlercreutz H, Salonen JT. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2003;163:1099-104
107. Vanharanta M, Voutilainen S, Lakka TA, van der LM, Adlercreutz H, Salonen JT. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999;354:2112-15
108. Ishikawa S, Soloway MS, Van der ZR, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141:1139-42
109. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-82
110. Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573-8
111. Furuya Y, Nozaki T, Nagakawa O, Fuse H. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002;49:85-90
112. Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002;89:710-13
113. Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur Urol 2000; 38:655-62
114. Vermeulen A, Deslypere JP. Testicular endocrine function in the ageing male. Maturitas 1985;7:273-9
115. Voorspoels J, Remon JP, Eechaute W, De Sy W. Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs. Pharm Res 1996;13:1228-32
116. Baisley KJ, Boyce MJ, Bukofzer S, Pradhan R, Warrington SJ. Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin. J Endocrinol 2002; 175:813-19
117. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7alpha- methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998;83:4212-19
118. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467-72
119. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002;17:2080-6
120. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-70
121. Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002;168:1985-8
122. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-25
123. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hiran K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001; 24:188-90
124. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47:59-65
125. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31
126. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553-7
127. Strom SS, Yamamura Y, Duphorne CM, et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 1999;33:20-5
128. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82
129. Hillman GG, Fortnan JD, Kucuk O, et al. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res 2001; 7:382-90
130. Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000;92:595-604
131. Kobayashi T, Nakata T, Kuzumaki T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 2002;176:17-23
132. Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 2000;38:116-22
133. Mitchell JH, Duthie SJ, Collins AR. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr Cancer 2000;38:223-8
134. Elmore E, Luc TT, Steele VE, Redpath JL. Comparative tissue-specific toxicities of 20 cancer preventive agents using cultured cells from 8 different normal human epithelia. In Vitro Mol Toxicol 2001;14:191-207
135. Pollard M, Wolter W, Sun L. Diet and the duration of testosterone- dependent prostate cancer in Lobund-Wistar rats. Cancer Lett 2001; 173:127-31
136. Urban D, Irwin W, Kirk M, et al The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001;165:294-300
137. Ornish DM, Lee KL, Fair WR, Pettengill EB, Carroll PR. Dietary trial in prostate cancer: early experience and implications for clinical trial design. Urology 2001;57:200-1
138. Stattin P, Adlercreutz H, Tenkanen L, et al. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002;99:124-9
139. Zalata AA, Christophe AB, Depuydt CE, Schoonjans F, Comhaire FH. White blood cells cause oxidative damage to the fatty acid composition of phospholipids of human spermatozoa. Int J Androl 1998;21:154-62
140. Comhaire FH, Christophe AB, Zalata AA, Dhooge WS, Mahmoud AM, Depuydt CE. The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids 2000;63:159-65
141. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:893-9
142. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Jr., Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003;95:1578-86
143. Bianchini F, Elmstahl S, Martinez-Garcia C, et al. Oxidative DNA damage in human lymphocytes: correlations with plasma levels of alpha-tocopherol and carotenoids. Carcinogenesis 2000; 21:321-4
144. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003;12:518-26
145. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6
146. Tran K, Chan AC. Comparative uptake of alpha- and gamma-tocopherol by human endothelial cells. Lipids 1992;27:38-41
147. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan LJ. Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci U S A 1993;90:1771-5
148. Nomura AM, Stemmermann GN, Lee J, Craft NE. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997;6:487-91
149. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23
150. Giovannucci E. Gamma-tocopherol: a new player in prostate cancer prevention? J Natl Cancer Inst 2000;92:1966-7
151. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr 1985;115:807-13
152. Handelman GJ, Epstein WL, Peerson J, Spiegelman D, Machlin LJ, Dratz EA. Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. Am J Clin Nutr 1994;59:1025-32
153. Behrens WA, Madere R. Mechanisms of absorption, transport and tissue uptake of RRR-alpha-tocopherol and d-gamma-tocopherol in the white rat. J Nutr 1987;117:1562-9
154. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4
155. Brawley OW, Barnes S, Farnes H. The future of prostate cancer prevention. Ann N Y Acad Sci 2001;952:145-52
156. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24
157. Nomura AM, Lee J, Stemmermann GN, Combs GF, Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7
158. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8
159. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12
160. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-30
161. Lowe GM, Booth LA, Young AJ, Bilton RF. Lycopene and beta-carotene protect against oxidative damage in HT29 cells at low concentrations but rapidly lose this capacity at higher doses. Free Radic Res 1999;30:141-51
162. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93:1872-9
163. Newcomer LM, King IB, Wicklund KG, Stanford JL. The association of fatty acids with prostate cancer risk. Prostate 2001;47:262-8
164. De Stefani E, Deneo-Pellegrini H, Boffetta P, Ronco A, Mendilaharsu M. Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev 2000;9:335-8
165. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Men who consume vegetable oils rich in monounsaturated fat: their dietary patterns and risk of prostate cancer (New Zealand). Cancer Causes Control 2000;11:609-15
166. Bito T, Roy S, Sen CK, Packer L. Pine bark extract pycnogenol downregulates IFN-gamma-induced adhesion of T cells to human keratinocytes by inhibiting inducible ICAM-1 expression. Free Radic Biol Med 2000;28:219-27
167. Cho KJ, Yun CH, Packer L, Chung AS. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 2001;928:141-56
168. Cho KJ, Yun CH, Yoon DY, et al. Effect of bioflavonoids extracted from the bark of Pinus maritima on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 264.7. Toxicol Appl Pharmacol 2000;168:64-71